EichorEICHOR
Location: Saint Petersburg Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Saint Petersburg

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor
Phase 2 · Saint Petersburg State University-Clinic of advanced medical · Merck Sharp & Dohme LLC · NCT04924075
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophreni
Phase 3 · Saint-Petersburg GUZ Psychiatric Hospital No.1 n.a. P.P. Kas · Gedeon Richter Plc. · NCT03817502
Effect of Kidney Replacement Therapy with Polymethylmethacrylate Membranes on Pruritus-related Quality of Life in Patien
NA · Saint Petersburg State University Hospital · Saint Petersburg State University, Russia · NCT06671535
The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke
Phase 3 · Saint Petersburg State Budgetary Healthcare Institution "Cit · Tatchempharmpreparaty, JSC · NCT07167550
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Phase 1/Phase 2 · Skyline Therapeutics (US) Inc. · NCT05986864
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular
Phase 1 · Federal State Budgetary Institution National Medical Researc · Pfizer · NCT03460977
A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic
Phase 1 · Private Healthcare Institution "Clinical Hospital "RZD-Medic · R-Pharm · NCT07543744
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerabilit
Phase 3 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT07517263
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in
Phase 3 · Russian Scientific Research Institute of Hematology and Bloo · Merck Sharp & Dohme LLC · NCT03486873
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult
Phase 3 · Pfizer · NCT07222800
Sore Throat After Open Neck Elective Surgery
Phase 4 · Saint Petersburg State University Hospital · Saint Petersburg State University, Russia · NCT07124650
Intrapleural Ropivacaine Infusion in Cardiac Surgery
Phase 4 · Saint-Petersburg university hospital · Saint Petersburg State University, Russia · NCT07116343
Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug
Phase 3 · Federal State Budgetary Institution "A. A. Smorodintsev Rese · NPO Petrovax · NCT06834100
PPG vs. ICG in Gastrointestinal Resections
NA · High-Tech Clinic Beloostrov · Saint Petersburg State University, Russia · NCT06222645
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or I
Phase 2 · Hoffmann-La Roche · NCT05039619
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Phase 1/Phase 2 · National Medical Research Center VA Almazov · BioInvent International AB · NCT04752826
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemo
Phase 3 · SBHI Children's City Multidisciplinary Clinical Specialized · Amgen · NCT03633708
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Phase 2 · Department of Tumor Growth Biology, N.N. Petrov Institute of · N.N. Petrov National Medical Research Center of Oncology · NCT06229340
A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therapy in Pediatric Patients With Duchenne Mu
Phase 1/Phase 2 · Saint Petersburg State Pediatric Medical University · AO GENERIUM · NCT07673809
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Phase N/A · Stryker Instruments · NCT03072927
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
Phase 2 · Mechnikov State Medical University ( Site 1803) · Merck Sharp & Dohme LLC · NCT04665037
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Ex
Phase 1/Phase 2 · I.P. Pavlov First Saint Petersburg State Medical University · Kidney Cancer Research Bureau · NCT07292168
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
Phase 3 · EyePoint Pharmaceuticals, Inc. · NCT07449936
Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery
NA · Saint-Petersburg State University Hospital · Unity Health Toronto · NCT04754022
The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients
Phase 3 · North-West State Medical University named after I.I. Mechnik · Materia Medica Holding · NCT06901297
Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases
Phase 2/Phase 3 · Saint-Petersburg State Research Institute of Phthisiopulmono · R-Pharm International, LLC · NCT06440746
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult
Phase 3 · Regeneron Pharmaceuticals · NCT06541704
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
Phase 2 · Saint Petersburg State University Hospital · Saint Petersburg State University, Russia · NCT06374602
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and
Phase 2 · Apellis Pharmaceuticals, Inc. · NCT07215390
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
Phase 3 · EyePoint Pharmaceuticals, Inc. · NCT07449923
Look up another city
Look up another condition